Is there any clinical advantage to using milrinone versus dobutamine in cardiogenic shock?

No Clear Clinical Advantage Between Milrinone and Dobutamine in Cardiogenic Shock

Based on the most recent and highest-quality evidence, there is no significant clinical advantage of milrinone over dobutamine (or vice versa) in terms of mortality, mechanical circulatory support requirements, or major adverse events in cardiogenic shock patients. The 2023 Canadian Cardiovascular Society guidelines, citing the DOREMI trial, explicitly state that the choice between these agents is "nowadays less controversial" given their similar clinical outcomes 1.

Key Evidence from DOREMI Trial

The landmark DOREMI trial (2021) directly compared milrinone versus dobutamine in 192 cardiogenic shock patients and found 2:

• Primary composite outcome: 49% (milrinone) vs 54% (dobutamine); RR 0.90 (95% CI 0.69-1.19), p=0.47
• In-hospital mortality: 37% vs 43%; RR 0.85 (95% CI 0.60-1.21) - no significant difference
• Mechanical circulatory support: 12% vs 15% - no significant difference
• Renal replacement therapy: 22% vs 17% - no significant difference

This high-quality randomized controlled trial provides the strongest evidence that neither agent demonstrates superiority for hard clinical outcomes including mortality, morbidity, or quality of life 1, 2.

Practical Differences to Guide Selection

While outcomes are equivalent, there are pharmacologic and practical differences that should guide individualized selection:

Choose Milrinone When:

• Tachycardia is present or undesirable - Milrinone causes less tachycardia than dobutamine 3, 4, 3
• Beta-blocker therapy - Dobutamine may be ineffective in patients recently on beta-blockers 5
• Non-ischemic cardiomyopathy - Some evidence suggests potential benefit 6

Choose Dobutamine When:

• Acute kidney injury is present - Critical interaction: milrinone's benefit is attenuated in patients with AKI, while dobutamine maintains relative efficacy 7
• Shorter duration of support needed - Dobutamine has shorter half-life and shorter duration of support in survivors (3.1 vs 5.0 days) 8
• Hypotension is prominent - Milrinone causes more profound hypotension due to longer half-life and vasodilatory effects 6
• Acute myocardial infarction - Guidelines recommend dobutamine as most commonly used inotrope in cardiogenic shock complicating ACS 9, 10

Critical Caveats

Acute Kidney Injury Modulates Treatment Effect

A crucial post-hoc analysis of DOREMI revealed that AKI significantly modulates the relative efficacy of these agents 7:

• In patients without AKI: milrinone showed lower risk of primary outcome and death
• In patients with AKI: this benefit was completely attenuated (p for interaction = 0.02 for primary outcome, 0.04 for death)

This is the single most important clinical factor for agent selection - check for AKI before choosing.

Vasopressor Co-Administration

Both agents cause vasodilation and may require concurrent vasopressor support 6:

• Norepinephrine is preferred as first-line vasopressor in cardiogenic shock 9, 10, 11
• Milrinone particularly may require vasopressor support to maintain RV perfusion pressure, especially with pulmonary hypertension 12

Arrhythmia Risk

Both agents increase arrhythmia risk, though comparative rates are similar 2, 13:

• Supraventricular and ventricular arrhythmias occur with both 14
• Close ECG monitoring mandatory during infusion 14
• Milrinone may require more antiarrhythmic agents (56% vs 44.5%) 15

Dosing Considerations

• Milrinone: Load 50 mcg/kg over 10 minutes, then 0.375 mcg/kg/min 3
• Dobutamine: 5-10 mcg/kg/min (lower doses 2-5 mcg/kg/min may suffice) 3, 16, 3
• Milrinone's longer half-life means effects persist longer after discontinuation 6

Guideline Recommendations

The 2016 ESC guidelines state that in cardiogenic shock 9, 10:

• Dobutamine is the most commonly used adrenergic inotrope (Class IIb, Level C)
• PDE3 inhibitors (milrinone) may be another option, especially in non-ischemic patients
• Rather than combining multiple inotropes, consider mechanical circulatory support for inadequate response

The 2018 global perspective on vasoactive agents confirms: "Studies comparing these two agents suggest similar clinical outcomes although milrinone has a longer half-life and is associated with more profound hypotension" 6.

Bottom Line Algorithm

1. Check for AKI - If present, favor dobutamine 7
2. Assess heart rate - If tachycardic, favor milrinone 3, 4, 3
3. Evaluate blood pressure - If borderline hypotensive, favor dobutamine (or ensure vasopressor ready) 6
4. Consider etiology - If acute MI, favor dobutamine; if non-ischemic, either acceptable 6, 9, 10
5. Plan for vasopressor - Have norepinephrine available regardless of choice 9, 10, 11
6. Monitor closely - Both require continuous ECG and arterial line monitoring 9, 10

The evidence does not support routine preference of one agent over the other for mortality or major morbidity reduction - selection should be based on the specific hemodynamic and clinical phenotype rather than expectations of survival benefit 1, 2.